search
Back to results

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Primary Purpose

Burns

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device
Mepilex® Ag Wound Dressing
Conventional autografting (only when indicated)
Sponsored by
Avita Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Burns focused on measuring Pediatric, Burns, Partial-thickness

Eligibility Criteria

1 Year - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female patients aged 1 through 16 years (inclusive) with a partial-thickness thermal burn injury.
  2. The patient has a thermal burn injury that is:

    1. ≤ 30% TBSA (exclusive of superficial areas) and
    2. ≤ 10% of the burn injury TBSA is a full-thickness burn.
  3. The Index Burn must be a clean partial-thickness burn injury > or = to 160 cm2 and between 2-20% BSA (inclusive).
  4. The Index Burn may not cover the face, hand, foot or the perineum/genitalia (Note: a patient with wounds in these areas may be enrolled but the Index Burn Area may not include these areas).
  5. The patient and/or guardian agrees to comply with all compulsory study procedures and visit schedule.
  6. The patient and/or parent/guardian agrees to abstain from any other treatment for closure of the Index Burn for the duration of the study, unless medically necessary.
  7. The patient and/or parent/guardian agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study.
  8. In the opinion of the investigator, the patient and/or parent/guardian must be able to:

    1. Understand the full nature and purpose of the study, including possible risks and adverse events,
    2. Understand instruction, and
    3. Provide voluntary informed written consent/assent as appropriate for study participation.

Exclusion Criteria:

  1. Not able to understand English or Spanish.
  2. Burns caused by chemicals, electricity or radiation.
  3. Patients presenting with ONLY 3rd degree / full-thickness wounds which require immediate autografting.
  4. Burn injury has had prior treatment for definitive closure.
  5. Patients for whom use of sedation/general anesthesia is not medically appropriate.
  6. Superficial / trivial burns or burns that in the investigator's opinion appear to be healing sufficiently such that care under this protocol would be inappropriate.
  7. Patient requires immediate or staged surgical procedures for closure of their partial-thickness burns.
  8. Conditions, e.g., previous burn injury to study area, poor nutritional status, poorly controlled diabetes mellitus (HbA1c>9%), that in the investigator's opinion may compromise subject safety or trial objectives.
  9. Current use of medications, e.g., immunosuppressive agents (excluding inhaled corticosteroids), that in the investigator's opinion may compromise subject safety or trial objectives.
  10. Inhalation injury.
  11. Active infection, cellulitis or need for immediate grafting at the planned treatment areas.
  12. Concerns for parent/guardian's ability to provide appropriate follow-up care.
  13. Subjects with a known hypersensitivity to trypsin or compound sodium lactate for irrigation solution.
  14. Subjects with a known sensitivity to silver.
  15. In post-pubescent girls, pregnant or breast-feeding (pregnancy test should be performed in accordance with local institutional requirements).
  16. Immediate life-threatening condition or life expectancy less than one year.
  17. Previous randomization within this investigation.

Post-Randomization Inclusion Criteria (prior to treatment):

  1. Patient randomized (and will be treated) within 72 hours from the time of the burn injury.
  2. Patient continues to meet all pre-randomization inclusion criteria.

Post-Randomization Exclusion Criteria (prior to treatment):

1. Incidental finding of any pre-randomization exclusion criteria.

Consented subjects who do not meet the post-randomization eligibility criteria and did not receive study treatment will be followed through the Day 28 visit and then withdrawn from the study. The criteria for which exclusion was based will be documented.

Sites / Locations

  • Arizona Burn Center / Valleywise Health
  • University of South Florida Tampa General Hospital
  • University Medical Center New Orleans
  • University of North Carolina
  • Wake Forest Baptist Medical Center
  • Saint Christopher's Hospital for Children
  • Medical University of South Carolina
  • Evan Hayes Burn Center, Virginia Commonwealth University
  • University of Washington Regional Burn Center at Harborview Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

RECELL® Autologous Cell Harvesting Device

Mepilex® Ag Wound Dressing

Arm Description

RECELL + Telfa™ Clear and Xeroform™ dressings Conventional autografting (only when indicated)

Mepilex® Ag Wound Dressing Conventional autografting (only when indicated)

Outcomes

Primary Outcome Measures

Incidence of Index Burns With Day 10 Healing
Day 10 healing will be evaluated by an observer blinded to treatment allocation with confirmation at Day 28

Secondary Outcome Measures

Incidence of Day 21 Healing of the Index Burn
Incidence of Day 21 healing of the Index Burn confirmed on Day 28
Incidence of Conventional Autografting to Achieve Healing of the Index Burn
Incidence of conventional autografting to achieve healing of the Index Burn

Full Information

First Posted
July 20, 2018
Last Updated
August 1, 2023
Sponsor
Avita Medical
Collaborators
Biomedical Advanced Research and Development Authority
search

1. Study Identification

Unique Protocol Identification Number
NCT03626701
Brief Title
RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years
Official Title
A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RES® (Regenerative Epidermal Suspension) Prepared With the RECELL® Device Compared to Standard of Care Dressings for Treatment of Partial-thickness Burns in Infants, Children and Adolescents (Aged 1-16 Years)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Terminated
Why Stopped
In June 2021, the US FDA approved expanded use of the RECELL System for treatment of acute full-thickness thermal burns in patients 1-month of age and older (removing the prior limitation of use in patients younger than 18 years of age).
Study Start Date
March 3, 2020 (Actual)
Primary Completion Date
June 23, 2021 (Actual)
Study Completion Date
June 3, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avita Medical
Collaborators
Biomedical Advanced Research and Development Authority

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL treatment of partial-thickness burn injuries, can safely and effectively increase the incidence of Day 10 healing compared with a standardized wound dressing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Burns
Keywords
Pediatric, Burns, Partial-thickness

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Blinded Evaluator/Observer - local burn specialist Independent Reviewer
Allocation
Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RECELL® Autologous Cell Harvesting Device
Arm Type
Experimental
Arm Description
RECELL + Telfa™ Clear and Xeroform™ dressings Conventional autografting (only when indicated)
Arm Title
Mepilex® Ag Wound Dressing
Arm Type
Active Comparator
Arm Description
Mepilex® Ag Wound Dressing Conventional autografting (only when indicated)
Intervention Type
Device
Intervention Name(s)
RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device
Intervention Description
Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
Intervention Type
Combination Product
Intervention Name(s)
Mepilex® Ag Wound Dressing
Intervention Description
Application of Mepilex® Ag Wound Dressing
Intervention Type
Procedure
Intervention Name(s)
Conventional autografting (only when indicated)
Intervention Description
When indicated, conventional autografting in accordance with Investigator's standard practice
Primary Outcome Measure Information:
Title
Incidence of Index Burns With Day 10 Healing
Description
Day 10 healing will be evaluated by an observer blinded to treatment allocation with confirmation at Day 28
Time Frame
10 Days post-treatment
Secondary Outcome Measure Information:
Title
Incidence of Day 21 Healing of the Index Burn
Description
Incidence of Day 21 healing of the Index Burn confirmed on Day 28
Time Frame
Day 21, confirmed on Day 28
Title
Incidence of Conventional Autografting to Achieve Healing of the Index Burn
Description
Incidence of conventional autografting to achieve healing of the Index Burn
Time Frame
Through Day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients aged 1 through 16 years (inclusive) with a partial-thickness thermal burn injury. The patient has a thermal burn injury that is: ≤ 30% TBSA (exclusive of superficial areas) and ≤ 10% of the burn injury TBSA is a full-thickness burn. The Index Burn must be a clean partial-thickness burn injury > or = to 160 cm2 and between 2-20% BSA (inclusive). The Index Burn may not cover the face, hand, foot or perineum/genitalia (Note: a patient with wounds in these areas may be enrolled but the Index Burn Area may not include these areas). The patient and/or guardian agrees to comply with all compulsory study procedures and visit schedule. The patient and/or parent/guardian agrees to abstain from any other treatment for closure of the Index Burn for the duration of the study, unless medically necessary. The patient and/or parent/guardian agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study. In the opinion of the investigator, the patient and/or parent/guardian must be able to: Understand the full nature and purpose of the study, including possible risks and adverse events, Understand instruction, and Provide voluntary informed written consent/assent as appropriate for study participation. Exclusion Criteria: Not able to understand English or Spanish. Burns caused by chemicals, electricity or radiation. Patients presenting with only 3rd-degree/full-thickness wounds which require immediate autografting. Burn injury has had prior treatment for definitive closure. Patients for whom use of sedation/general anesthesia is not medically appropriate. Superficial/trivial burns or burns that in the investigator's opinion appear to be healing sufficiently such that care under this protocol would be inappropriate. Patient requires immediate or staged surgical procedures for closure of their partial-thickness burns. Conditions, e.g., previous burn injury to study area, poor nutritional status, poorly controlled diabetes mellitus (HbA1c >9%), that in the investigator's opinion may compromise subject safety or trial objectives. Current use of medications, e.g., immunosuppressive agents (excluding inhaled corticosteroids), that in the investigator's opinion may compromise subject safety or trial objectives. Inhalation injury. Active infection, cellulitis or need for immediate grafting at the planned treatment areas. Concerns for parent/guardian's ability to provide appropriate follow-up care. Subjects with a known hypersensitivity to trypsin or compound sodium lactate for irrigation solution. Subjects with a known sensitivity to silver. In post-pubescent girls, pregnant or breast-feeding (pregnancy test should be performed in accordance with local institutional requirements). Immediate life-threatening condition or life expectancy less than one year. Previous randomization within this investigation. Post-Randomization Inclusion Criteria (prior to treatment): Patient randomized (and will be treated) within 72 hours from the time of the burn injury. Patient continues to meet all pre-randomization inclusion criteria. Post-Randomization Exclusion Criteria (prior to treatment): 1. Incidental finding of any pre-randomization exclusion criteria. Consented subjects who do not meet the post-randomization eligibility criteria and did not receive study treatment will be followed through the Day 28 visit and then withdrawn from the study. The criteria for which exclusion was based will be documented.
Facility Information:
Facility Name
Arizona Burn Center / Valleywise Health
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85008
Country
United States
Facility Name
University of South Florida Tampa General Hospital
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
University Medical Center New Orleans
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599-7600
Country
United States
Facility Name
Wake Forest Baptist Medical Center
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Saint Christopher's Hospital for Children
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19134
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Evan Hayes Burn Center, Virginia Commonwealth University
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23219
Country
United States
Facility Name
University of Washington Regional Burn Center at Harborview Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

We'll reach out to this number within 24 hrs